| __timestamp | Ascendis Pharma A/S | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 19698000 | 30945000 |
| Thursday, January 1, 2015 | 40528000 | 40853000 |
| Friday, January 1, 2016 | 66022000 | 45187000 |
| Sunday, January 1, 2017 | 99589000 | 53514000 |
| Monday, January 1, 2018 | 140281000 | 55329000 |
| Tuesday, January 1, 2019 | 191621000 | 62413000 |
| Wednesday, January 1, 2020 | 260904000 | 65192000 |
| Friday, January 1, 2021 | 295867000 | 70603000 |
| Saturday, January 1, 2022 | 379624000 | 87140000 |
| Sunday, January 1, 2023 | 413454000 | 92493000 |
| Monday, January 1, 2024 | 307004000 | 96664000 |
Unleashing insights
In the competitive landscape of biotechnology, innovation is the key to success. Ascendis Pharma A/S and Bio-Techne Corporation exemplify this through their research and development (R&D) investments over the past decade. Ascendis Pharma A/S has shown a remarkable commitment to innovation, increasing its R&D spending by over 2,000% from 2014 to 2023. In contrast, Bio-Techne Corporation has maintained a steady growth in R&D expenses, with a 200% increase over the same period.
Ascendis Pharma's aggressive investment strategy is evident, with its R&D spending peaking at approximately 413 million in 2023, compared to Bio-Techne's 92 million. This disparity highlights Ascendis Pharma's prioritization of innovation, potentially positioning it as a leader in the biotech industry. However, Bio-Techne's consistent growth strategy also underscores its commitment to innovation, albeit at a more measured pace.
Comparing Innovation Spending: Novartis AG and Bio-Techne Corporation
Research and Development Expenses Breakdown: Pfizer Inc. vs Ascendis Pharma A/S
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S
Research and Development Expenses Breakdown: Summit Therapeutics Inc. vs Bio-Techne Corporation
R&D Insights: How Bio-Techne Corporation and Lantheus Holdings, Inc. Allocate Funds
Research and Development Investment: Bio-Techne Corporation vs CRISPR Therapeutics AG
R&D Insights: How Bio-Techne Corporation and Soleno Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Bio-Techne Corporation vs Perrigo Company plc
Research and Development Expenses Breakdown: Bio-Techne Corporation vs Travere Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and Jazz Pharmaceuticals plc
R&D Spending Showdown: Ascendis Pharma A/S vs Opthea Limited
Ascendis Pharma A/S vs Wave Life Sciences Ltd.: Strategic Focus on R&D Spending